Royal DSM NV in talks to acquire culture and enzymes business of Cargill

By Admin
Royal DSM NV, Dutch chemical and pharmaceutical group is in exclusive discussions to buy Cargills culture and enzymes business. It also plans to have a...

Royal DSM NV, Dutch chemical and pharmaceutical group is in exclusive discussions to buy Cargill’s culture and enzymes business.

It also plans to have a larger share of over €1 billion global market for cultures and enzymes. 

Cargill’s cultures and enzymes business is a global leading manufacturer of cultures and enzymes for the dairy and meat industries with manufacturing operations in Wisconsin- the U.S. and France and also generates net sales of about €45 million per year.  

The Cargill cultures and enzymes business has a strong pipeline of new products built on three pillars of technology namely culture texture toolbox, fast acidification for cheese yield improvements and culture flavor systems.

The combination of the Cargill cultures and enzymes business with its own dairy business will be highly complementary, the reports said.  This will also enable it to propel sales growth as well as capture sizable synergies in global manufacturing footprint.  

Hans-Christian Ambjerg, President DSM Food Specialities said, “This acquisition would be another great step in achieving our ambitious growth strategy.” Mr. Ambjerg also said, “Combining both businesses would allow us to serve our customers faster with one of the most versatile offerings in cultures and enzymes in the global dairy industry.”

Royal DSM is a global science-based company. It offers solutions that nourish, protect, and improve performance in global markets like pharmaceuticals, medical devices, automotive paints, life protection and bio-based materials.


Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare